Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joanne Wilkinson

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
International Journal of Family Medicine|April 11, 2014
Measuring staff empowerment regarding health care for clients with intellectual disabilitiesJoanne Wilkinson, Nechama W Greenwood, Claire Tienwey Wang, et al.
Intellectual and Developmental Disabilities|April 15, 2014
Evaluating representativeness and cancer screening outcomes in a state department of developmental services databaseJoanne Wilkinson, Emily Lauer, Nechama W Greenwood, et al.
European Journal of Gastroenterology & Hepatology|October 2, 2018
Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux diseaseJoanne Wilkinson, Alan Wade, S Jane Thomas, et al.
Journal of Digestive Diseases|September 14, 2016
Alginate antacid (Gaviscon DA) chewable tablets reduce esophageal acid exposure in Chinese patients with gastroesophageal reflux disease and heartburn symptomsYao Zong Yuan, Jing Yuan Fang, Duo Wu Zou, et al.
Scandinavian Journal of Gastroenterology|November 10, 2016
Psychometric evaluation of a daily gastro-oesophageal reflux disease symptom measurePeter Bytzer, Christina Reimer, Gary Smith, et al.
Drug Development and Industrial Pharmacy|November 25, 2018
Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action)Joanne Wilkinson, Khalid Abd-Elaziz, Izaak den Daas, et al.
Contemporary Clinical Trials|June 7, 2021
Three week compared to seven week run-in period length and the assessment of pre-randomization adherence: A study within a trialDavid Collister, Lawrence Mbuagbaw, Gordon Guyatt, et al.
The New England Journal of Medicine|April 5, 2016
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular DiseaseEva M Lonn, Jackie Bosch, Patricio López-Jaramillo, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
International Journal of Family Medicine|April 11, 2014
Measuring staff empowerment regarding health care for clients with intellectual disabilitiesJoanne Wilkinson, Nechama W Greenwood, Claire Tienwey Wang, et al.
Intellectual and Developmental Disabilities|April 15, 2014
Evaluating representativeness and cancer screening outcomes in a state department of developmental services databaseJoanne Wilkinson, Emily Lauer, Nechama W Greenwood, et al.
European Journal of Gastroenterology & Hepatology|October 2, 2018
Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux diseaseJoanne Wilkinson, Alan Wade, S Jane Thomas, et al.
Journal of Digestive Diseases|September 14, 2016
Alginate antacid (Gaviscon DA) chewable tablets reduce esophageal acid exposure in Chinese patients with gastroesophageal reflux disease and heartburn symptomsYao Zong Yuan, Jing Yuan Fang, Duo Wu Zou, et al.
Scandinavian Journal of Gastroenterology|November 10, 2016
Psychometric evaluation of a daily gastro-oesophageal reflux disease symptom measurePeter Bytzer, Christina Reimer, Gary Smith, et al.
Drug Development and Industrial Pharmacy|November 25, 2018
Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action)Joanne Wilkinson, Khalid Abd-Elaziz, Izaak den Daas, et al.
Contemporary Clinical Trials|June 7, 2021
Three week compared to seven week run-in period length and the assessment of pre-randomization adherence: A study within a trialDavid Collister, Lawrence Mbuagbaw, Gordon Guyatt, et al.
The New England Journal of Medicine|April 5, 2016
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular DiseaseEva M Lonn, Jackie Bosch, Patricio López-Jaramillo, et al.
Pageof 2